Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 27 recruiting now early-phase tilt #117 of 28,707 conditions

Advanced Malignant Solid Neoplasm: early-phase trial registry

27 of 109 indexed Advanced Malignant Solid Neoplasm trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #117 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

109 US clinical trials · 27 currently recruiting · #117 of 28,707 conditions by registered trial count

Advanced Malignant Solid Neoplasm: 109 US clinical trials tracked, 27 recruiting.

Advanced Malignant Solid Neoplasm is the subject of 109 registered US clinical trials on ClinicalTrials.gov, 27 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 99 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 67 of these trials.

Enrollment posture brief

Registry condition advanced-malignant-solid-neoplasm

OPEN 27 | RECR 25% | LATE 1 | EARLY 99 | RANK #117 | SPON 67

Volume-matched condition peers

Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)

Breast Carcinoma58.9%Quality of Life40.4%Fatigue30%Advanced Malignant Solid (th…25%Hepatitis C12%
Open-enrollment share among volume-matched conditions near Advanced Malignant Solid Neoplasm

Advanced Malignant Solid Neoplasm lists 27 open slots (25% of 109 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Advanced Malignant Solid Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Advanced Malignant Solid Neoplasm is recruiting below its size-band peers.

    27 of 109 indexed trials (24.8%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Advanced Malignant Solid Neoplasm research.

    National Cancer Institute (NCI) accounts for 67 of 109 trials (61.5%). 17 distinct sponsors appear on at least one study for this condition label.

  3. Most Advanced Malignant Solid Neoplasm trials plan to enrol fewer than 100 people.

    Median target enrolment is 45 among the 109 trials that report a genuine target (sentinel values excluded). 86 of those (78.9%) plan for fewer than 100 participants.

  4. Advanced Malignant Solid Neoplasm research is mostly interventional.

    106 interventional and 3 observational studies make up this index (97.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 144Phase 255Phase 31

Open and recent trials

109 total, page 2 of 3

ACTIVE NOT RECRUITING Phase 2 54 participants

Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study

National Cancer Institute (NCI)

NCT03872427
ACTIVE NOT RECRUITING Phase 2 53 participants

Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)

National Cancer Institute (NCI)

NCT04439344
ACTIVE NOT RECRUITING Phase 2 50 participants

Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)

National Cancer Institute (NCI)

NCT04439318
ACTIVE NOT RECRUITING Phase 1 50 participants

FID-007 in Treating Participants With Advanced Solid Tumors

University of Southern California

NCT03537690
ACTIVE NOT RECRUITING Phase 1 49 participants

EphA2 siRNA in Treating Patients With Advanced or Recurrent Solid Tumors

M.D. Anderson Cancer Center

NCT01591356
ACTIVE NOT RECRUITING Phase 2 49 participants

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)

National Cancer Institute (NCI)

NCT06390865
ACTIVE NOT RECRUITING Phase 2 44 participants

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)

National Cancer Institute (NCI)

NCT06357975
ACTIVE NOT RECRUITING Phase 1 44 participants

Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors

M.D. Anderson Cancer Center

NCT05038839
ACTIVE NOT RECRUITING Phase 2 43 participants

Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)

National Cancer Institute (NCI)

NCT06390839
ACTIVE NOT RECRUITING Phase 2 40 participants

Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)

National Cancer Institute (NCI)

NCT04439136
ACTIVE NOT RECRUITING Phase 2 40 participants

Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)

National Cancer Institute (NCI)

NCT04439201
ACTIVE NOT RECRUITING Phase 1 39 participants

Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations

National Cancer Institute (NCI)

NCT03842228
ACTIVE NOT RECRUITING Phase 2 38 participants

Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)

National Cancer Institute (NCI)

NCT04439110
ACTIVE NOT RECRUITING Phase 2 35 participants

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)

National Cancer Institute (NCI)

NCT06400238
ACTIVE NOT RECRUITING Phase 2 35 participants

Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)

National Cancer Institute (NCI)

NCT06390852
ACTIVE NOT RECRUITING Phase 2 35 participants

Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)

National Cancer Institute (NCI)

NCT04439227
ACTIVE NOT RECRUITING Phase 2 35 participants

Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)

National Cancer Institute (NCI)

NCT04439331
ACTIVE NOT RECRUITING Phase 2 35 participants

Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)

National Cancer Institute (NCI)

NCT06357988
ACTIVE NOT RECRUITING Phase 2 35 participants

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)

National Cancer Institute (NCI)

NCT04439188
ACTIVE NOT RECRUITING Phase 2 35 participants

Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)

National Cancer Institute (NCI)

NCT04439279
ACTIVE NOT RECRUITING Phase 2 35 participants

Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)

National Cancer Institute (NCI)

NCT05490771
ACTIVE NOT RECRUITING Phase 2 35 participants

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)

National Cancer Institute (NCI)

NCT06308822
ACTIVE NOT RECRUITING Phase 2 35 participants

Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)

National Cancer Institute (NCI)

NCT04439123
ACTIVE NOT RECRUITING Phase 1 35 participants

Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma

National Cancer Institute (NCI)

NCT01303341
ACTIVE NOT RECRUITING Phase 2 35 participants

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)

National Cancer Institute (NCI)

NCT06385496
ACTIVE NOT RECRUITING Phase 2 35 participants

Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)

National Cancer Institute (NCI)

NCT06400225
ACTIVE NOT RECRUITING Phase 2 35 participants

Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)

National Cancer Institute (NCI)

NCT04439292
ACTIVE NOT RECRUITING Phase 2 35 participants

Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)

National Cancer Institute (NCI)

NCT06400251
ACTIVE NOT RECRUITING Phase 2 30 participants

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

OHSU Knight Cancer Institute

NCT06630325
ACTIVE NOT RECRUITING Phase 1 30 participants

Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

National Cancer Institute (NCI)

NCT02535312
ACTIVE NOT RECRUITING Phase 2 24 participants

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)

National Cancer Institute (NCI)

NCT04439149
ACTIVE NOT RECRUITING Phase 1 23 participants

PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

NCT03218826
ACTIVE NOT RECRUITING Phase 2 20 participants

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)

National Cancer Institute (NCI)

NCT06360575
ACTIVE NOT RECRUITING Phase 2 20 participants

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

NCT03698994
ACTIVE NOT RECRUITING Phase 2 20 participants

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

NCT03210714
ACTIVE NOT RECRUITING Phase 2 19 participants

Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)

National Cancer Institute (NCI)

NCT06385483
ACTIVE NOT RECRUITING Phase 2 19 participants

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

National Cancer Institute (NCI)

NCT06303167
ACTIVE NOT RECRUITING Phase 1 15 participants

Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

Roswell Park Cancer Institute

NCT02650986
ACTIVE NOT RECRUITING Phase 1 14 participants

Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors

National Cancer Institute (NCI)

NCT04616534
ACTIVE NOT RECRUITING Phase 1 14 participants

Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors

M.D. Anderson Cancer Center

NCT02389309
ACTIVE NOT RECRUITING Phase 2 13 participants

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

NCT03213652
ACTIVE NOT RECRUITING Phase 1 13 participants

Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study

National Cancer Institute (NCI)

NCT04197713
ACTIVE NOT RECRUITING Phase 2 10 participants

Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)

National Cancer Institute (NCI)

NCT06390826
ACTIVE NOT RECRUITING Phase 2 9 participants

Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

NCT03213704
ACTIVE NOT RECRUITING Phase 1 8 participants

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

National Cancer Institute (NCI)

NCT04514484
ACTIVE NOT RECRUITING Phase 2 5 participants

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)

National Cancer Institute (NCI)

NCT04439266
ACTIVE NOT RECRUITING Phase 2 4 participants

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)

National Cancer Institute (NCI)

NCT04439253
ACTIVE NOT RECRUITING Phase 2 4 participants

Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)

National Cancer Institute (NCI)

NCT04439357
COMPLETED 223 participants

Distress Associated with Coronavirus Disease 2019 and Telehealth on Supportive Care Patients with Advanced Cancer

M.D. Anderson Cancer Center

NCT05058339
COMPLETED Phase 2 208 participants

MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations

National Cancer Institute (NCI)

NCT01827384
← Previous Page 2 of 3 Next →

Phase Distribution

PhaseTrial count
Phase 1 44
Phase 2 55
Phase 3 1

Top Sponsors

National Cancer Institute (NCI) 67 trials
M.D. Anderson Cancer Center 20 trials
OHSU Knight Cancer Institute 3 trials
Mayo Clinic 3 trials
Roswell Park Cancer Institute 2 trials
University of California, Davis 2 trials
University of Southern California 2 trials
Ronald Levy 1 trials
Tianhong Li 1 trials
RasCal Therapeutics 1 trials

Named interventions

Most-linked intervention names on Advanced Malignant Solid Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Biospecimen Collection Procedure
39 trials
Computed Tomography Procedure
32 trials
Biopsy Procedure Procedure
31 trials
Magnetic Resonance Imaging Procedure
20 trials
Laboratory Biomarker Analysis Other
14 trials
Questionnaire Administration Other
10 trials
Echocardiography Test Procedure
10 trials
Pharmacological Study Other
6 trials

US sites by state

Facility locations filed on Advanced Malignant Solid Neoplasm trials. A trial with sites in several states counts in each.

Pennsylvania 38 trials
Texas 30 trials
California 28 trials
Florida 14 trials
Maryland 12 trials
Colorado 12 trials
Arizona 12 trials
New York 10 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Advanced Malignant Solid Neoplasm page

109 registered trials, 27 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Advanced Malignant Solid Neoplasm condition card totals 109 registered trials; most-linked intervention Biospecimen Collection; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.